Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
Background: There have been studies reporting the crucial roles of Dipeptidyl-peptidase 4 (DPP4) in colorectal cancer (CRC) initiation and progression, whereas DPP4-inhibitors are safe Food and Drug Association (FDA)-approved drugs for treating diabetes. This study aims to investigate the associatio...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/14/3588 |
| _version_ | 1797527465489334272 |
|---|---|
| author | Lui Ng Dominic Chi-Chung Foo Carlos King-Ho Wong Abraham Tak-Ka Man Oswens Siu-Hung Lo Wai-Lun Law |
| author_facet | Lui Ng Dominic Chi-Chung Foo Carlos King-Ho Wong Abraham Tak-Ka Man Oswens Siu-Hung Lo Wai-Lun Law |
| author_sort | Lui Ng |
| collection | DOAJ |
| description | Background: There have been studies reporting the crucial roles of Dipeptidyl-peptidase 4 (DPP4) in colorectal cancer (CRC) initiation and progression, whereas DPP4-inhibitors are safe Food and Drug Association (FDA)-approved drugs for treating diabetes. This study aims to investigate the association between DPP4-inhibitor treatment and the prognosis of CRC patients. Methods: Clinical data of CRC patients with diabetes and the prescription of DPP4-inhibitors who had undergone curative surgery in our hospital between January 2006 and December 2015 were retrieved. Their survival data and immune cell population in circulatory blood were compared to those treated with metformin. Results: The DPP4-inhibitor patient group showed a significantly better 5-year disease-free survival (median DFS = 1733 days, 95% CI = 1596 to 1870 days) when compared to the metformin group (<i>p</i> = 0.030, median DFS = 1382 days, 95% CI = 1246 to 1518 days). 33 out of the 92 patients in the metformin group showed recurrence whereas only 3 of the 26 patients in the DPP4-inhibitor group showed recurrence (<i>p</i> = 0.033). Cox regression analysis demonstrated that DPP4-inhibitor application is a favorable factor associated with a lower risk of recurrence (Hazard ratio = 0.200, <i>p</i> = 0.035). Furthermore, our results suggested that the immune cell profile of CRC patients is a potential biomarker for response to DPP4-inhibitor treatment. Conclusion: This study demonstrated the association of DPP4-inhibitor treatment with a better prognosis of CRC patients. |
| first_indexed | 2024-03-10T09:44:07Z |
| format | Article |
| id | doaj.art-7cb37f51509f4b8a86862e0a1bbf081d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:44:07Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7cb37f51509f4b8a86862e0a1bbf081d2023-11-22T03:25:49ZengMDPI AGCancers2072-66942021-07-011314358810.3390/cancers13143588Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center StudyLui Ng0Dominic Chi-Chung Foo1Carlos King-Ho Wong2Abraham Tak-Ka Man3Oswens Siu-Hung Lo4Wai-Lun Law5Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong KongDepartment of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong KongDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong KongDepartment of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong KongDepartment of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong KongDepartment of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong KongBackground: There have been studies reporting the crucial roles of Dipeptidyl-peptidase 4 (DPP4) in colorectal cancer (CRC) initiation and progression, whereas DPP4-inhibitors are safe Food and Drug Association (FDA)-approved drugs for treating diabetes. This study aims to investigate the association between DPP4-inhibitor treatment and the prognosis of CRC patients. Methods: Clinical data of CRC patients with diabetes and the prescription of DPP4-inhibitors who had undergone curative surgery in our hospital between January 2006 and December 2015 were retrieved. Their survival data and immune cell population in circulatory blood were compared to those treated with metformin. Results: The DPP4-inhibitor patient group showed a significantly better 5-year disease-free survival (median DFS = 1733 days, 95% CI = 1596 to 1870 days) when compared to the metformin group (<i>p</i> = 0.030, median DFS = 1382 days, 95% CI = 1246 to 1518 days). 33 out of the 92 patients in the metformin group showed recurrence whereas only 3 of the 26 patients in the DPP4-inhibitor group showed recurrence (<i>p</i> = 0.033). Cox regression analysis demonstrated that DPP4-inhibitor application is a favorable factor associated with a lower risk of recurrence (Hazard ratio = 0.200, <i>p</i> = 0.035). Furthermore, our results suggested that the immune cell profile of CRC patients is a potential biomarker for response to DPP4-inhibitor treatment. Conclusion: This study demonstrated the association of DPP4-inhibitor treatment with a better prognosis of CRC patients.https://www.mdpi.com/2072-6694/13/14/3588colorectal cancerDPP4CD26DPP4-inhibitorgliptinimmune cell |
| spellingShingle | Lui Ng Dominic Chi-Chung Foo Carlos King-Ho Wong Abraham Tak-Ka Man Oswens Siu-Hung Lo Wai-Lun Law Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study Cancers colorectal cancer DPP4 CD26 DPP4-inhibitor gliptin immune cell |
| title | Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study |
| title_full | Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study |
| title_fullStr | Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study |
| title_full_unstemmed | Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study |
| title_short | Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study |
| title_sort | repurposing dpp 4 inhibitors for colorectal cancer a retrospective and single center study |
| topic | colorectal cancer DPP4 CD26 DPP4-inhibitor gliptin immune cell |
| url | https://www.mdpi.com/2072-6694/13/14/3588 |
| work_keys_str_mv | AT luing repurposingdpp4inhibitorsforcolorectalcanceraretrospectiveandsinglecenterstudy AT dominicchichungfoo repurposingdpp4inhibitorsforcolorectalcanceraretrospectiveandsinglecenterstudy AT carloskinghowong repurposingdpp4inhibitorsforcolorectalcanceraretrospectiveandsinglecenterstudy AT abrahamtakkaman repurposingdpp4inhibitorsforcolorectalcanceraretrospectiveandsinglecenterstudy AT oswenssiuhunglo repurposingdpp4inhibitorsforcolorectalcanceraretrospectiveandsinglecenterstudy AT wailunlaw repurposingdpp4inhibitorsforcolorectalcanceraretrospectiveandsinglecenterstudy |